SIOUX FALLS, South Dakota, May 31, 2017 /PRNewswire/ --
DAKOTA Life Sciences, a division of Kasten Corporation, (OTC Pink: KAST) offers award-winning life sciences products powered by proprietary drug delivery technologies. In the area of topical delivery of medications through soft tissue, one of these technologies is known as Site Specific Penetration Technology (SSPT[TM]).
This DAKOTA Life Sciences’ drug delivery technology enables direct application of medications at the site where the drug is needed, rather than relying on delivery systemically through the blood stream. This is a powerful benefit for many people who must avoid interaction with other drugs they may be taking. Many people also prefer this type of site-specific drug delivery for fighting infection because it avoids the negative effect of systemic antibiotics on the body’s beneficial bacteria such as in the gut or genito-urinary tract.
However according to Steve Keough, the President of Kasten and a Co-inventor of the technology said, “This tissue penetrating site-specific feature is also very important for people with circulation problems caused by smoking, diabetes, peripheral artery disease, and other illnesses. This capability is essential for both our Over-The-Counter products as well as our prescription products designed to combat pre-existing serious infections that have not healed when other medications were tried.”
Most remarkably, the SSPT brand of drug delivery system restores resistance-prone pharmaceuticals, like early generation tetracycline, into newly active, high efficacy drugs once again capable of reliably killing both resistant and non-resistant bacteria. This unique DAKOTA Life Sciences technology is designed to reduce the risk of formation of future resistant strains by effectively reducing the water activity level in the bacteria. The company believes that this causes aspects of the bacterial replication process to become much less effective. This feature, combined with the excellent penetration of the formulation through tissue, creates an antibiotic formulation uniquely equipped for protecting those people who are more susceptiple to infections due to other chronic diseases.
This proprietary technology has proven capable of delivering many different families of molecules. For example, it is quite effective at delivery of conventional pain relieving medications to specific sites, such as knees and other joints. The SSPT delivery system is also a superb platform for delivery of different active agents in the medical cannabinoid family, such as THC for the psychotropic medical benefits or more targeted relief of other serious indications without the psychotropic impact. In an era where even certain cancers have developed resistance profiles to cancer medications, the SSPT drug delivery system is an essential therapeutic tool in the physician’s arsenal for improved drug delivery and adds tremendous value to the Company’s technology portfolio.
The variety of drug delivery platforms within DAKOTA Life Sciences/Kasten, and products that use those platforms, gives patients and medical providers results they have only dreamed of. As Keough reminds all new employees at the Company, “We don’t just offer exceptional products, we give people well-founded hope for better health outcomes and relief from misery.”
About Kasten, Inc.
Kasten, Inc. (OTC Pink: KAST) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals designed to prevent and treat serious conditions arising both in hospital and community settings. We are principally focused on delivering solutions to those people who cannot afford to miss a day of work, but who are burdened by high risk of morbidity and healthcare costs.
Forward-Looking Statements - This press release contains ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Kasten, Inc. undertakes no obligation to update such statements.
CONTACT:
Kasten Inc./DAKOTA Life Sciences
pr@dakotalifesci.com
+1-888-679-3679
http://www.kastenbiopharma.com
